Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations - AJMC.com Managed Markets Network

Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar SB5 and a high-concentration version.

While 2023 is becoming known as an important year for biosimilars because of the introduction of at least 7 adalimumab (Humira) biosimilars in the United States, there are nuances with the formulatio… [+3624 chars]

full article...